OMIC singulargenomics.com Earnings per share increase in current year
Can Singular Genomics Systems (OMIC) grow given the workforce reductions and the focus on clinical trials? The annual earnings per share growth trajectory confirms the potential, while 96.30 remains the current level of the metric, and instrument assembly relies on external optics. The strategy resulted in transferring electronics to contract manufacturers and outsourcing laboratory service support.
Analytical breakdowns and data insights for company Singular Genomics Systems (OMIC)
- market value and analyst target forecast:
- market capitalization data:
- business book valuation details:
- debt and solvency information:
Debt to Capital Singular Genomics Systems|OMIC - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio singulargenomics.com|OMIC - Company Debts|Debts to Book Value Singular Genomics Corp|OMIC - Company Long-Term Debt|Company Current Liabilities Singular Genomics|Interim Coverage Ratio singulargenomics.com
- net income and valuation multiples indicators:
OMIC - Net Profit|Future Profit Singular Genomics Systems|OMIC - Price to Earnings Ratio|Market Cap to Projected Earnings Singular Genomics Corp|OMIC - Price/Earnings to Growth Multiple|Business Value to Operating Income Before Depreciation Singular Genomics Corp|OMIC - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Singular Genomics|OMIC - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months singulargenomics.com|OMIC - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Singular Genomics Systems
Basic company analysis:OMIC Singular Genomics Systems, Inc.
This metric measures the year-over-year dynamics of net income per share, allowing for an objective assessment of the business's earnings growth rate. By analyzing the percentage increase in net income per share over the year, an investor filters out market noise and identifies the real value of 96.30. This is critical for Singular Genomics (OMIC), as high R&D and marketing expenses associated with deploying the sequencer base constrain free cash flow generation.
Main competitors
Tempus Labs (TEM) - Earnings growth in current year|Earnings per share growth in current year Qiagen Group|IONS: Earnings per share increase in current year|Net earnings per share growth this year RGEN (Repligen Corporation)|RNA (aviditybiosciences.com) - Earnings per share increase in current year|Earnings growth in current year CRSP (CRISPR Therapeutics)|Net earnings per share change in current year GeneDx Holdings|Ultragenyx Pharma - Earnings growth in current year|Earnings per share growth rate in current year Beam Tx|Sarepta Therapeutics, Inc. (SRPT) - Earnings per share growth in current year|Earnings per share growth this year TWST|Earnings per share growth in current year 10x Genomics|Earnings per share growth rate in current year Intellia Therapeutics Inc NTLA|Earnings per share growth in current year Stoke (STOK)|Net earnings per share growth this year BioLife BLFS|Earnings growth in current year WVE (Wave Life Sciences)|Expected net earnings per share growth this year mazetx.com (MAZE)|Sionna Therapeutics - Earnings growth in current year|Prime Medicine Inc (PRME) - Net earnings per share growth this year|Taysha (TSHA) - Earnings per share growth in current year|QURE - Expected net earnings per share growth this year|Net earnings per share growth this year MGTX|RGNX: Earnings per share increase in current year|Earnings per share growth in current year Solid Biosciences (SLDB)|Expected net earnings per share growth this year Ocugen Inc|Pacific Biosciences of California - Net earnings per share growth this year|Benitec Corp (BNTC) - Earnings per share growth rate in current year|DSGN - Earnings per share growth in current year|Expected net earnings per share growth this year rocketpharma.com RCKT|FDMT (4D Molecular Therapeutics, Inc.) - Net earnings per share growth this year|LXEO: Net earnings per one share growth for the current year|KRRO (Korro Bio Inc.) - Earnings growth in current year|Earnings per share growth rate in current year Editas Corp EDIT|Earnings per share growth in current year Silence Therapeutics (SLN)|Net earnings per share growth this year proqr.com PRQR|Earnings per share growth in current year Codexis CDXS|Expected net earnings per share growth this year Sangamo Therapeutics Inc. (SGMO)|NAUT - Earnings per share growth in current year|Earnings per share growth rate in current year Metagenomi Therapeutics|Precision BioSciences, Inc. (DTIL) - Earnings per share growth in current year|Net earnings per share growth this year Generation Bio|BOLD (Boundless Bio) - Earnings growth in current year|Exicure Corp (XCUR) - Expected net earnings per share growth this year|Earnings growth in current year IMNN|Net earnings per share growth this year phiopharma.com PHIO|Earnings growth in current year MBIO (Mustang Bio)|RNAZ: Earnings per share growth this year|BNGO - Earnings per share growth in current year|APDN (Applied DNA Sciences Inc) - Earnings per share growth this year|BLUE: Earnings growth in current year|ImmunoPrecise Antibodies Ltd. (IPA) - Earnings growth in current year|Earnings per share growth in current year Omega Therapeutics|regulusrx.com (RGLS) - Expected net earnings per share growth this year|Earnings growth in current year SYRS|Expected net earnings per share growth this year Telesis Bio Inc.|Earnings per share growth in current year TRACON TCON|UBX: Earnings per share growth this year
